IL145301A0 - 1-arenesulfonyl-2-aryl-pyrrolidine and piperidine derivatives for the treatment of cns disorders - Google Patents
1-arenesulfonyl-2-aryl-pyrrolidine and piperidine derivatives for the treatment of cns disordersInfo
- Publication number
- IL145301A0 IL145301A0 IL14530100A IL14530100A IL145301A0 IL 145301 A0 IL145301 A0 IL 145301A0 IL 14530100 A IL14530100 A IL 14530100A IL 14530100 A IL14530100 A IL 14530100A IL 145301 A0 IL145301 A0 IL 145301A0
- Authority
- IL
- Israel
- Prior art keywords
- arenesulfonyl
- pyrrolidine
- aryl
- treatment
- cns disorders
- Prior art date
Links
- 150000003053 piperidines Chemical class 0.000 title 1
- RWRDLPDLKQPQOW-UHFFFAOYSA-N tetrahydropyrrole Substances C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/46—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with hetero atoms directly attached to the ring nitrogen atom
- C07D207/48—Sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Addiction (AREA)
- Pain & Pain Management (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Vascular Medicine (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Hospice & Palliative Care (AREA)
- Urology & Nephrology (AREA)
- Psychology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyrrole Compounds (AREA)
- Hydrogenated Pyridines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP99106004 | 1999-03-25 | ||
| PCT/EP2000/002431 WO2000058285A1 (en) | 1999-03-25 | 2000-03-18 | 1-arenesulfonyl-2-aryl-pyrrolidine and piperidine derivatives for the treatment of cns disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL145301A0 true IL145301A0 (en) | 2002-06-30 |
Family
ID=8237852
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL14530100A IL145301A0 (en) | 1999-03-25 | 2000-03-18 | 1-arenesulfonyl-2-aryl-pyrrolidine and piperidine derivatives for the treatment of cns disorders |
Country Status (34)
| Country | Link |
|---|---|
| US (1) | US6284785B1 (es) |
| EP (1) | EP1165510B1 (es) |
| JP (1) | JP3590589B2 (es) |
| KR (1) | KR100452648B1 (es) |
| CN (1) | CN1150165C (es) |
| AR (1) | AR028817A1 (es) |
| AT (1) | ATE305451T1 (es) |
| AU (1) | AU765212B2 (es) |
| BR (1) | BR0009278A (es) |
| CA (1) | CA2368418C (es) |
| CO (1) | CO5050296A1 (es) |
| CZ (1) | CZ20013402A3 (es) |
| DE (1) | DE60022867T2 (es) |
| DK (1) | DK1165510T3 (es) |
| ES (1) | ES2249249T3 (es) |
| HK (1) | HK1044944B (es) |
| HR (1) | HRP20010682A2 (es) |
| HU (1) | HUP0200284A3 (es) |
| IL (1) | IL145301A0 (es) |
| JO (1) | JO2274B1 (es) |
| MA (1) | MA26779A1 (es) |
| MX (1) | MXPA01009623A (es) |
| MY (1) | MY125295A (es) |
| NO (1) | NO319948B1 (es) |
| NZ (1) | NZ514037A (es) |
| PE (1) | PE20001583A1 (es) |
| PL (1) | PL204436B1 (es) |
| RU (1) | RU2248350C2 (es) |
| SI (1) | SI1165510T1 (es) |
| TR (1) | TR200102789T2 (es) |
| TW (1) | TW575561B (es) |
| WO (1) | WO2000058285A1 (es) |
| YU (1) | YU67601A (es) |
| ZA (1) | ZA200107689B (es) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20010052503A (ko) | 1998-06-03 | 2001-06-25 | 다니엘 피. 맥컬럼 | N-헤테로사이클릭 카복실산 또는 카복실산 등입체의n-결합된 설폰아미드 |
| US6589978B2 (en) | 2000-06-30 | 2003-07-08 | Hoffman-La Roche Inc. | 1-sulfonyl pyrrolidine derivatives |
| US20040267010A1 (en) * | 2001-02-02 | 2004-12-30 | Forbes Ian Thomson | Sulfonamide compounds, their preparation and use |
| TW200302717A (en) * | 2002-02-06 | 2003-08-16 | Schering Corp | Novel gamma secretase inhibitors |
| EP1667983A4 (en) * | 2003-09-23 | 2010-07-21 | Merck Sharp & Dohme | PYRAZOL MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS |
| WO2005079795A2 (en) * | 2004-02-20 | 2005-09-01 | Novartis Ag | Dpp-iv inhibitors for treating neurodegeneration and cognitive disorders |
| EP1758884A2 (en) * | 2004-05-20 | 2007-03-07 | Elan Pharmaceuticals, Inc. | N-cyclic sulfonamido inhibitors of gamma secretase |
| EP1803709B1 (en) | 2004-09-30 | 2013-01-02 | Takeda Pharmaceutical Company Limited | Proton pump inhibitors |
| CA2620333A1 (en) | 2005-08-26 | 2007-03-01 | Braincells, Inc. | Neurogenesis by muscarinic receptor modulation |
| EP2258359A3 (en) | 2005-08-26 | 2011-04-06 | Braincells, Inc. | Neurogenesis by muscarinic receptor modulation with sabcomelin |
| ATE504567T1 (de) | 2005-08-30 | 2011-04-15 | Takeda Pharmaceutical | 1-heterocyclylsulfonyl, 2-aminomethyl, 5- (hetero-) aryl-substitutierte 1-h-pyrrolderivate als säuresekretionshemmer |
| AU2006304787A1 (en) | 2005-10-21 | 2007-04-26 | Braincells, Inc. | Modulation of neurogenesis by PDE inhibition |
| EP2314289A1 (en) | 2005-10-31 | 2011-04-27 | Braincells, Inc. | Gaba receptor mediated modulation of neurogenesis |
| US20100216734A1 (en) | 2006-03-08 | 2010-08-26 | Braincells, Inc. | Modulation of neurogenesis by nootropic agents |
| EP2021000A2 (en) | 2006-05-09 | 2009-02-11 | Braincells, Inc. | Neurogenesis by modulating angiotensin |
| JP2009536667A (ja) | 2006-05-09 | 2009-10-15 | ブレインセルス,インコーポレイティド | 5ht受容体介在性の神経新生 |
| MX2009002496A (es) | 2006-09-08 | 2009-07-10 | Braincells Inc | Combinaciones que contienen un derivado de 4-acilaminopiridina. |
| US20100184806A1 (en) | 2006-09-19 | 2010-07-22 | Braincells, Inc. | Modulation of neurogenesis by ppar agents |
| US8933105B2 (en) | 2007-02-28 | 2015-01-13 | Takeda Pharmaceutical Company Limited | Pyrrole compounds |
| ES2423289T3 (es) | 2008-08-27 | 2013-09-19 | Takeda Pharmaceutical Company Limited | Compuestos de pirrol |
| US20100216805A1 (en) | 2009-02-25 | 2010-08-26 | Braincells, Inc. | Modulation of neurogenesis using d-cycloserine combinations |
| GB201702221D0 (en) | 2017-02-10 | 2017-03-29 | Univ Of Sussex | Compounds |
| US10603313B2 (en) | 2017-07-31 | 2020-03-31 | Chiromics, LLC | Allosteric modulators of the mu opioid receptor |
| GB201803340D0 (en) | 2018-03-01 | 2018-04-18 | Univ Of Sussex | Compounds |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK167393B1 (da) * | 1985-12-30 | 1993-10-25 | Roussel Uclaf | 1-sulfonyl-2-oxo-pyrrolidinderivater, deres fremstilling og farmaceutiske praeparater med indhold deraf |
| US5194439A (en) * | 1990-04-06 | 1993-03-16 | John Wyeth & Brother Limited | N-(2,3-dihydro-1,4-benzodioxinyl)-N-substituted aminopyrido-fused cycloalkanes |
| DE69205287T2 (de) * | 1991-12-18 | 1996-03-14 | Schering Corp., Kenilworth, N.J. | Imidazolylalkyl- piperazin und -diazepin derivate als histamin h3 agonisten/antagonisten. |
| FR2685325B1 (fr) * | 1991-12-20 | 1994-02-04 | Adir Cie | Nouveaux derives de pyrrolidine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent. |
| GB9612884D0 (en) * | 1996-06-20 | 1996-08-21 | Smithkline Beecham Plc | Novel compounds |
-
2000
- 2000-03-13 TW TW89104504A patent/TW575561B/zh active
- 2000-03-18 PL PL350679A patent/PL204436B1/pl not_active IP Right Cessation
- 2000-03-18 EP EP00910863A patent/EP1165510B1/en not_active Expired - Lifetime
- 2000-03-18 IL IL14530100A patent/IL145301A0/xx unknown
- 2000-03-18 HK HK02106320.6A patent/HK1044944B/zh not_active IP Right Cessation
- 2000-03-18 CA CA002368418A patent/CA2368418C/en not_active Expired - Fee Related
- 2000-03-18 CZ CZ20013402A patent/CZ20013402A3/cs unknown
- 2000-03-18 DK DK00910863T patent/DK1165510T3/da active
- 2000-03-18 RU RU2001126570/04A patent/RU2248350C2/ru not_active IP Right Cessation
- 2000-03-18 HU HU0200284A patent/HUP0200284A3/hu unknown
- 2000-03-18 CN CNB008055300A patent/CN1150165C/zh not_active Expired - Fee Related
- 2000-03-18 SI SI200030753T patent/SI1165510T1/sl unknown
- 2000-03-18 KR KR10-2001-7012227A patent/KR100452648B1/ko not_active Expired - Fee Related
- 2000-03-18 AT AT00910863T patent/ATE305451T1/de active
- 2000-03-18 MX MXPA01009623A patent/MXPA01009623A/es active IP Right Grant
- 2000-03-18 HR HR20010682A patent/HRP20010682A2/hr not_active Application Discontinuation
- 2000-03-18 JP JP2000607988A patent/JP3590589B2/ja not_active Expired - Fee Related
- 2000-03-18 TR TR2001/02789T patent/TR200102789T2/xx unknown
- 2000-03-18 BR BR0009278-9A patent/BR0009278A/pt active Search and Examination
- 2000-03-18 DE DE60022867T patent/DE60022867T2/de not_active Expired - Lifetime
- 2000-03-18 ES ES00910863T patent/ES2249249T3/es not_active Expired - Lifetime
- 2000-03-18 AU AU32915/00A patent/AU765212B2/en not_active Ceased
- 2000-03-18 WO PCT/EP2000/002431 patent/WO2000058285A1/en not_active Ceased
- 2000-03-18 YU YU67601A patent/YU67601A/sh unknown
- 2000-03-20 PE PE2000000241A patent/PE20001583A1/es not_active Application Discontinuation
- 2000-03-22 CO CO00020380A patent/CO5050296A1/es unknown
- 2000-03-23 JO JO200025A patent/JO2274B1/en active
- 2000-03-23 MY MYPI20001145A patent/MY125295A/en unknown
- 2000-03-23 AR ARP000101297A patent/AR028817A1/es unknown
- 2000-03-24 US US09/534,380 patent/US6284785B1/en not_active Expired - Fee Related
-
2001
- 2001-09-18 ZA ZA200107689A patent/ZA200107689B/xx unknown
- 2001-09-24 NO NO20014617A patent/NO319948B1/no unknown
- 2001-09-25 MA MA26339A patent/MA26779A1/fr unknown
-
2004
- 2004-01-30 NZ NZ514037A patent/NZ514037A/xx unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL145301A0 (en) | 1-arenesulfonyl-2-aryl-pyrrolidine and piperidine derivatives for the treatment of cns disorders | |
| IL149530A0 (en) | A pyrrolidineacetamide derivative alone or in combination for treatment of cns disorders | |
| HUP0400914A3 (en) | Methods of treatment of mitochondrial disorders | |
| AU5309400A (en) | Methods and compositions for the treatment of neuroleptic and related disorders using sertindole derivatives | |
| IL155589A0 (en) | Novel amidoalkyl-piperidine and amidoalkyl-piperazine derivatives useful for the treatment of nervous system disorders | |
| AU8187701A (en) | Sulfonyl-pyrrolidine derivatives useful for the treatment of neurological disorders | |
| SI1231920T1 (sl) | Uporaba epinastina za zdravljenje alergijskega renitisa/konjuktivitisa | |
| AU6910600A (en) | Methods for the treatment of mental disorders | |
| AU5908300A (en) | Prevention and treatment of amyloid-associated disorders | |
| AU2002215047A1 (en) | Isoquinoline derivatives useful in the treatment of cns disorders | |
| IL154051A0 (en) | 4-,5-,6-, and 7-indole derivatives useful for the treatment of cns disorders | |
| AU7388101A (en) | Indole derivatives useful for the treatment of cns disorders | |
| HUP0104701A3 (en) | 3-tetrahydropyridin-4-yl indoles for treatment of psychotic disorders and medicaments containing the compounds | |
| EP1181308A4 (en) | METHODS OF TREATING NEURONAL DEMENTIA ASSOCIATED WITH ATROPHY | |
| AU1028501A (en) | Isoquinoline and quinazoline derivatives for the treatment of cns disorders | |
| AU8173801A (en) | Indole derivatives useful for the treatment of cns disorders | |
| CZ20011872A3 (cs) | Isonipekotamidy pro léčbu onemocnění zprostředkovaných integriny | |
| PL351554A1 (en) | Osanetant in the treatment of mood disorders | |
| IL153254A0 (en) | Indole derivatives useful for the treatment of cns disorders | |
| AU2080201A (en) | Treatment of addiction disorders | |
| IL131399A0 (en) | The use of aryl-cyclohexylamine derivatives against cns disorders | |
| AU6007900A (en) | Azetidine carboxamide derivatives for the treatment of cns disorders | |
| IL139018A0 (en) | Paroxetine 10-camphorsulfonate for treatment of cns disorders | |
| IL153351A0 (en) | Indole derivatives useful for the treatment of cns disorders | |
| IL153234A0 (en) | Indole derivatives useful for the treatment of cns disorders |